NS5A inhibitors in the treatment of hepatitis C

Journal of Hepatology

Volumn 59, Issue 2, 2013, Pages 375-382

  Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

Daclatasvir; Hepatitis C virus; NS5A inhibitor; Resistance

Indexed keywords

ABT 267; ABT 450; ACH 2928; ACH 3102; ANTIVIRUS AGENT; ASUNAPREVIR; BMS 824393; DACLATASVIR; GSK 2336805; IDX 719; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA; PLACEBO; PPI 668; RIBAVIRIN; RITONAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; DRUG MECHANISM; DRUG POTENCY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS GENE; VIRUS INHIBITION; VIRUS MORPHOLOGY;

CEVR; COMPLETE EARLY VIROLOGIC RESPONSE; DAA; DACLATASVIR; DIRECT ACTING ANTIVIRAL; HCV; HEPATITIS C VIRUS; IFN; INTERFERON; INTERNAL RIBOSOME ENTRY SITE; IRES; NONSTRUCTURAL; NS; NS5A INHIBITOR; RAPID VIROLOGIC RESPONSE; RDRP; RESISTANCE; RNA-DEPENDENT RNA POLYMERASE; RVR; SUSTAINED VIROLOGICAL RESPONSE; SVR; UNTRANSLATED REGION; UTR;

ADMINISTRATION, ORAL; ANILIDES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARBAMATES; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84880299420     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.030     Document Type: Review

References (76)

1. Global Burden of Hepatitis C Working Group Global burden of disease (GBD) for hepatitis C J Clin Pharmacol 44 2004 20 29
2. World Health Organization. Global alert and response, Hepatitis C. < http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html >.
3. H. Toyoda, T. Kumada, S. Kiriyama, Y. Sone, M. Tanikawa, and Y. Hisanaga Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy Clin Infect Dis 40 2005 e49 54
4. F. Poordad, and D. Dieterich Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents J Viral Hepat 19 2012 449 464
5. G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 2004 S35 S50
6. Victrelis (boceprevir). Package insert 2005. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
7. Incivek (telaprevir). Package insert 2012. Vertex Pharmaceuticals, Cambridge, MA, USA.
8. J.E. Reynolds, A. Kaminski, H.J. Kettinen, K. Grace, B.E. Clarke, and A.R. Carroll Unique features of internal initiation of hepatitis C virus RNA translation EMBO J 14 1995 6010 6020
9. A.A. Kolykhalov, S.M. Feinstone, and C.M. Rice Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA J Virol 70 1996 3363 3371
10. T.L. Foster, T. Belyaeva, N.J. Stonehouse, A.R. Pearson, and M. Harris All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding J Virol 84 2010 9267 9277
11. P. Andre, G. Perlemuter, A. Budkowska, C. Brechot, and V. Lotteau Hepatitis C virus particles and lipoprotein metabolism Semin Liver Dis 25 2005 93 104
12. E. Blanchard, S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, and C. Wychowski Hepatitis C virus entry depends on clathrin-mediated endocytosis J Virol 80 2006 6964 6972
13. Q.L. Choo, K.H. Richman, J.H. Han, K. Berger, C. Lee, and C. Dong Genetic organization and diversity of the hepatitis C virus Proc Natl Acad Sci U S A 88 1991 2451 2455
14. B.D. Lindenbach, and C.M. Rice Unravelling hepatitis C virus replication from genome to function Nature 436 2005 933 938
15. X. Hanoulle, A. Badillo, J.M. Wieruszeski, D. Verdegem, I. Landrieu, and R. Bartenschlager Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B J Biol Chem 284 2009 13589 13601
16. U. Chatterji, M.D. Bobardt, P. Lim, and P.A. Gallay Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes J Gen Virol 91 2010 1189 1193
17. A.K. Ghosh, R. Steele, K. Meyer, R. Ray, and R.B. Ray Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth J Gen Virol 80 1999 1179 1183
18. K.H. Lan, M.L. Sheu, S.J. Hwang, S.H. Yen, S.Y. Chen, and J.C. Wu HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis Oncogene 21 2002 4801 4811
19. N. Arima, C.Y. Kao, T. Licht, R. Padmanabhan, and Y. Sasaguri Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A J Biol Chem 276 2001 12675 12684
20. Higgs MR, Lerat H, Pawlotsky JM. Hepatitis C virus-induced activation of beta-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene, in press.
21. M.J. Evans, C.M. Rice, and S.P. Goff Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication Proc Natl Acad Sci U S A 101 2004 13038 13043
22. P. Neddermann, M. Quintavalle, C. Di Pietro, A. Clementi, M. Cerretani, and S. Altamura Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture J Virol 78 2004 13306 13314
23. R.A. Fridell, D. Qiu, L. Valera, C. Wang, R.E. Rose, and M. Gao Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 85 2011 7312 7320
24. T.L. Tellinghuisen, K.L. Foss, J.C. Treadaway, and C.M. Rice Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein J Virol 82 2008 1073 1083
25. T.K. Scheel, J. Prentoe, T.H. Carlsen, L.S. Mikkelsen, J.M. Gottwein, and J. Bukh Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems PLoS Pathog 8 2012 e1002696
26. Y. Shirota, H. Luo, W. Qin, S. Kaneko, T. Yamashita, and K. Kobayashi Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity J Biol Chem 277 2002 11149 11155
27. E.M. Quezada, and C.M. Kane The hepatitis C virus NS5A stimulates NS5B during in vitro RNA synthesis in a template specific manner Open Biochem J 3 2009 39 48
28. T.L. Foster, P. Gallay, N.J. Stonehouse, and M. Harris Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J Virol 85 2011 7460 7464
29. W. Cun, J. Jiang, and G. Luo The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus J Virol 84 2010 11532 11541
30. N. Appel, M. Zayas, S. Miller, J. Krijnse-Locker, T. Schaller, and P. Friebe Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly PLoS Pathog 4 2008 e1000035
31. W.J. Benga, S.E. Krieger, M. Dimitrova, M.B. Zeisel, M. Parnot, and J. Lupberger Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles Hepatology 51 2010 43 53
32. J. Guedj, H. Dahari, L. Rong, N.D. Sansone, R.E. Nettles, and S.J. Cotler Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci U S A 110 2013 3991 3996
33. P. Targett-Adams, E.J. Graham, J. Middleton, A. Palmer, S.M. Shaw, and H. Lavender Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action J Virol 85 2011 6353 6368
34. Targett-Adams P. NS5A inhibitors: picomolar power to combat hepatitis C virus? < http://www.hepatitiscnewdrugresearch.com/what-are-ns5a-inhibitors. html >.
35. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
36. J.A. Lemm, D. O'Boyle 2nd, M. Liu, P.T. Nower, R. Colonno, and M.S. Deshpande Identification of hepatitis C virus NS5A inhibitors J Virol 84 2010 482 491
37. L.A. Pelosi, S. Voss, M. Liu, M. Gao, and J.A. Lemm Effect on HCV replication by combinations of direct acting antivirals including NS5A inhibitor aaclatasvir Antimicrob Agents Chemother 56 2012 5230 5239
38. T. Masaki, R. Suzuki, K. Murakami, H. Aizaki, K. Ishii, and A. Murayama Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles J Virol 82 2008 7964 7976
39. M. Quintavalle, S. Sambucini, V. Summa, L. Orsatti, F. Talamo, and R. De Francesco Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors J Biol Chem 282 2007 5536 5544
40. C. Lee, H. Ma, J.Q. Hang, V. Leveque, E.H. Sklan, and M. Elazar The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein Virology 414 2011 10 18
41. J.M. Pawlotsky, and C. Hepatitis Virus population dynamics during infection Curr Top Microbiol Immunol 299 2006 261 284
42. C.S. Strahotin, and M. Babich Hepatitis C variability, patterns of resistance, and impact on therapy Adv Virol 2012 2012 267483
43. R.A. Fridell, C. Wang, J.H. Sun, D.R. O'Boyle, P. Nower, and L. Valera Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
44. S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, and H.A. Tatum Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 12 2012 671 677
45. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
46. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol, 2013; 58: 655-662.
47. C. Hezode, G.M. HIrschfield, W. Ghesquiere, W. Sievert, M. Rodriguez-Torres, and S.D. Shafran Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results Hepatology 56 2012 553A
48. M. Sulkowski, D. Gardiner, E. Lawitz, F. Hinestrosa, D. Nelson, and P. Thuluvath Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) J Hepatol 56 2012 S560
49. G.T. Everson, K.D. Sims, M. Rodriguez-Torres, C. Hezode, E. Lawitz, and M. Bourliere An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV) and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection Hepatology 56 2012 1517A
50. K.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D.R. Nelson, and S. Zeuzem A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection Hepatology 56 2012 1515A
51. Abbott Laboratories. Abbott's investigational interferon-free hepatitis C treatment regimen achieved SVR12 (observed data) rates in 99 percent of treatment-naive and 93 percent in prior null responders for genotype 1 patients in Phase 2b study. < http://www.abbott.com/news-media/press-releases/abbotts- investigational-interferonfree-hepatitis-c-treatment-regimen-achieved-svr12- observed-data.htm >.
52. G. Cheng, B. Peng, A. Corsa, M. Yu, M. Nash, and Y.J. Lee Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885 J Hepatol 56 2012 S464
53. E.J. Lawitz, D. Gruener, J.M. Hill, T. Marbury, L. Moorehead, and A. Mathias A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J Hepatol 57 2012 24 31
54. Gane EJ, Stedman CA, Hyland RH, Ding X, Pang PS, Symonds WT. ELECTRON: 100% SVR rate for once-daily sofosbuvir plus ledipasvir plus ribavirin given for 12 weeks in treatment-naïve and previously treated patients with HCV GT 1. Presented at the 20th conference on retroviruses and opportunistic infections. Atlanta, Georgia, March 3-6, 2013.
55. Safety and efficacy of sofosbuvir/GS-5885 fixed-dose combination (FDC) +/- ribavirin for the treatment of HCV. < http://clinicaltrials.gov/ct2/show/ NCT01701401?term=hepatitisc&cond=%22HepatitisCVirus%22&lup-s= 09%2F08%2F2012&lup-d=30 >.
56. A.J. Thompson, M.L. Shiffman, L. Rossaro, R. Ghalib, S.-H.B. Han, and K.L. Beavers Six weeks of a NS5A inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon/ribavirin (PR) achieves high SVR4 rates in genotype 1 IL28B CC treatment-naive HCV patients: interim results of a prospective, randomized trial Hepatology 56 2012 556A
57. Dose ranging of GSK2336805 in combination therapy. < http://clinicaltrials.gov/ct2/show/NCT01648140 >.
58. W. Spreen, D. Wilfret, D. Bechtel, K. Adkinson, Y. Lou, and L.H. Jones GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic hepatitis C (CHC) genotype 1 infection: results from a first time in human (FITH) single and repeat dose study Hepatology 54 2011 400A
59. Y. Zhao, G. Yang, J. Fabrycki, D. Patel, J. Wiles, and X. Wang In vitro combination studies of ACH-1625 (HCV NS3 protease inhibitor) & ACH-2928 (HCV NS5A inhibitor) in presence and absence of ribavirin Hepatology 52 2010 1214A
60. B. Vince, E. Lawitz, S. Searle, T. Marbury, H. Robison, and L. Robarge Novel NS5A inhibitor ACH-2928 phase 1 results in healthy volunteers and HCV GT-1 patients J Hepatol 56 2012 S480 S481
61. R. Nettles, X. Wang, S. Quadri, Y. Wu, M. Gao, and M. Belema BMS-824393 is a potent hepatitis C virus NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic G1 HCV infection (Abstract 1858) Hepatology 52 2010 1203A
62. Bilello JP, La Colla M, Chapron C, et al. The preclinical profile of the pan-genotypic HCV NS5A inhibitor IDX719 demonstrates its potential for combination therapy. In: seventh international workshop on hepatitis C-resistance and new compounds, June 28-29, 2012. < http://www.idenix.com/ hcv/Bilello%20HCV%20Resistance%20Workshop%202012.pdf >.
63. Zhou XJ, Vince B, Dubuc Patrick G, et al. Safety, pharmacokinetic and preliminary antiviral activity results from a first-in-human study of IDX719, a pan-genotypic novel HCV NS5A inhibitor. In: seventh international workshop on clinical pharmacology of hepatitis therapy, June 27, 2012. < http://www.idenix.com/hcv/IDX719-HCVClinPharmMtg-FINAL%206%2027%2012.pdf >.
64. D.L. Mayers, B. Vince, J.M. Hill, E. Lawitz, W.D. O'Riordan, and L.R. Webster IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV-infected subjects Hepatology 56 2012 1020A
65. Idenix Pharmaceuticals. Idenix pharmaceuticals announces collaboration with Janssen to initiate phase II all-oral combination studies including IDX719, simeprevir (TMC435) and TMC647055 for the treatment of hepatitis C virus (HCV). < http://files.shareholder.com/downloads/IDIX/2297933580x0x630925/c52eb4ea- 905e-4dd5-99fa-6e2ffc1b1388/IDIX-News-2013-1-28-General-Releases.pdf >.
66. Q. Huang, N. Huang, M. Lau, M. Bencsik, A. Huq, and A. Peng Resistance monitoring of HCV patients treated for three days with the NS5A inhibitor PPI-461 reveals rapid emergence of resistant HCV variants Hepatology 54 2011 536A
67. Presidio Pharmaceuticals. Presidio pharmaceuticals successfully completes phase 1 proof-of-concept for PPI-668, its potent HCV N5SA inhibitor, in Hepatitis C patients with Genotype-1 infection. < http://www.presidiopharma. com/ >.
68. J.P. Lalezari, G.C. Farrell, P.S. Shah, C. Schwab, D. Walsh, and P. Vig PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety Hepatology 56 2012 1065A 1066A
69. G. Yang, J. Wiles, D. Patel, Y. Zhao, J. Fabrycki, and S. Weinheimer Preclinical characteristics of ACH-3102; a novel NS5A inhibitor with improved potency against genotype-1A virus and variants resistant to 1st generation NS5A inhibitors J Hepatol 56 2012 S330
70. Y. Zhao, D. Patel, J.L. Fabrycki, S. Weinheimer, G. Yang, and W. Yang In vitro studies demonstrate a high probability of curing genotype 1 hepatitis C patients with combination of a novel NS3 protease inhibitor ACH-2684 and a novel NS5A inhibitor ACH-3102 Hepatology 56 2012 1071A
71. R.E. Nettles, H. Sevinksy, E. Chung, D. Burt, H. Xiao, and T. Marbury BMS-790052, a first-in-class potent hepatitis C virus NS5A inhibitor, demonstrates multiple-dose proof-of-concept in subjects with chronic GT1 HCV infection (potent, mean maximal 5.7 log reduction) Hepatology 52 2010 1214A
72. E. Lawitz Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects J Hepatol 56 2012 S469 S470
73. Achillion Pharmaceuticals. Achillion announces positive proof-of-concept data with ACH-3102. < http://ir.achillion.com/releasedetail.cfm?ReleaseID= 709768 >.
74. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
75. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
76. X. Gao, J.M. Stephens, J.A. Carter, S. Haider, and V.K. Rustgi Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 2012 335 343